Amphastar Pharmaceuticals EBITDA Margin 2012-2024 | AMPH
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Amphastar Pharmaceuticals (AMPH) over the last 10 years. The current EBITDA margin for Amphastar Pharmaceuticals as of June 30, 2024 is .
| Amphastar Pharmaceuticals EBITDA Margin Historical Data |
| Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
| 2024-06-30 |
$0.71B |
$0.30B |
41.37% |
| 2024-03-31 |
$0.68B |
$0.27B |
39.88% |
| 2023-12-31 |
$0.65B |
$0.25B |
38.29% |
| 2023-09-30 |
$0.60B |
$0.22B |
36.71% |
| 2023-06-30 |
$0.54B |
$0.16B |
29.57% |
| 2023-03-31 |
$0.52B |
$0.15B |
27.99% |
| 2022-12-31 |
$0.50B |
$0.13B |
26.71% |
| 2022-09-30 |
$0.48B |
$0.12B |
24.59% |
| 2022-06-30 |
$0.48B |
$0.12B |
25.00% |
| 2022-03-31 |
$0.46B |
$0.11B |
23.08% |
| 2021-12-31 |
$0.44B |
$0.09B |
21.23% |
| 2021-09-30 |
$0.41B |
$0.07B |
17.43% |
| 2021-06-30 |
$0.38B |
$0.05B |
13.28% |
| 2021-03-31 |
$0.37B |
$0.04B |
9.78% |
| 2020-12-31 |
$0.35B |
$0.03B |
9.14% |
| 2020-09-30 |
$0.34B |
$0.03B |
8.31% |
| 2020-06-30 |
$0.33B |
$0.03B |
7.78% |
| 2020-03-31 |
$0.33B |
$0.03B |
8.87% |
| 2019-12-31 |
$0.32B |
$0.02B |
5.59% |
| 2019-09-30 |
$0.33B |
$0.02B |
5.78% |
| 2019-06-30 |
$0.33B |
$0.02B |
5.85% |
| 2019-03-31 |
$0.32B |
$0.02B |
4.73% |
| 2018-12-31 |
$0.30B |
$0.01B |
2.71% |
| 2018-09-30 |
$0.27B |
$0.00B |
1.51% |
| 2018-06-30 |
$0.25B |
$-0.00B |
-0.81% |
| 2018-03-31 |
$0.24B |
$0.00B |
1.24% |
| 2017-12-31 |
$0.24B |
$0.01B |
5.83% |
| 2017-09-30 |
$0.24B |
$0.01B |
4.51% |
| 2017-06-30 |
$0.25B |
$0.02B |
8.00% |
| 2017-03-31 |
$0.25B |
$0.03B |
11.07% |
| 2016-12-31 |
$0.26B |
$0.03B |
12.16% |
| 2016-09-30 |
$0.27B |
$0.05B |
18.66% |
| 2016-06-30 |
$0.27B |
$0.04B |
14.93% |
| 2016-03-31 |
$0.25B |
$0.02B |
7.48% |
| 2015-12-31 |
$0.25B |
$0.01B |
2.78% |
| 2015-09-30 |
$0.23B |
$-0.01B |
-6.06% |
| 2015-06-30 |
$0.23B |
$-0.02B |
-7.93% |
| 2015-03-31 |
$0.22B |
$-0.01B |
-4.05% |
| 2014-12-31 |
$0.21B |
$-0.00B |
-1.90% |
| 2014-09-30 |
$0.21B |
$0.01B |
2.38% |
| 2014-06-30 |
$0.21B |
$0.01B |
5.74% |
| 2014-03-31 |
$0.22B |
$0.03B |
11.21% |
| 2013-12-31 |
$0.23B |
$0.03B |
12.61% |
| 2013-09-30 |
$0.23B |
$0.08B |
33.04% |
| 2013-06-30 |
$0.23B |
$0.13B |
57.33% |
| 2013-03-31 |
$0.21B |
$0.16B |
77.25% |
| 2012-12-31 |
$0.20B |
$0.20B |
100.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$2.469B |
$0.644B |
|
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.
|
